Oxycodone

Generic Name: Oxycodone

Brand Names: Endocet, Endodan Reformulated May 2009, Nalocet, Oxaydo, Oxy.IR, Oxycontin, Oxyneo, Percocet, Prolate, Rivacocet, Roxicet, Roxicodone, Roxybond, Targin, Targiniq, Xolox, Xtampza

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁NO_₄

CAS Number: 76-42-6

Unique Ingredient Identifier: CD35PMG570

Background: Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period. The first oxycodone containing product, Percodan, wa...

Indication: Oxycodone is indicated for the treatment of moderate to severe pain. There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.

Associated Conditions: Severe Acute Pain, Severe Pain, Severe, Chronic Pain, Acute, moderate Pain, Chronic, moderate Pain

Associated Therapies: -

Clinical Trials

Effect of Pregabalin on Immediate Post-operative and Longterm Pain

Phase 4

Completed

Conditions: Scoliosis
Spondylolisthesis

Interventions: Drug: Sugar pill
Drug: Pregabalin
Drug: Oxycodone

First Posted Date: 2015-06-08

Last Posted Date: 2020-10-19

Lead Sponsor: Turku University Hospital

Target Recruit Count: 64

Registration Number: NCT02464813

Locations: 🇫🇮
Turku University Hospital, Turku, Finland

Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease

Not Applicable

Conditions: Peripheral Arterial Disease

Interventions: Dietary Supplement: Fructose
Dietary Supplement: Magnesium oxide
Drug: Oxycodone
Drug: Pregabalin

First Posted Date: 2015-05-28

Last Posted Date: 2015-05-28

Lead Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Target Recruit Count: 150

Registration Number: NCT02455726

Dose Response Study of Dexmedetomidine in Orthopaedic Spine Surgery Patients

Phase 4

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Oxycodone
Drug: Dexmedetomidine

First Posted Date: 2015-05-27

Last Posted Date: 2020-09-22

Lead Sponsor: Turku University Hospital

Target Recruit Count: 107

Registration Number: NCT02454881

Locations: 🇫🇮
Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital, Turku, Finland

Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis

Phase 4

Conditions: Chronic Kidney Disease

Interventions: Drug: Oxycodone

First Posted Date: 2015-05-22

Last Posted Date: 2015-05-22

Lead Sponsor: Emerio & Lourdes Linares Research and Education Center

Target Recruit Count: 20

Registration Number: NCT02452437

Locations: 🇺🇸
Oscar A. Linares, MD, Dearborn, Michigan, United States

Clinical Trial on Individual Characteristics Affecting Pain Drug Therapy in Neonates

Phase 4

Completed

Conditions: Critical Illness

Interventions: Drug: oxycodone
Drug: propofol

First Posted Date: 2015-04-27

Last Posted Date: 2019-02-04

Lead Sponsor: Turku University Hospital

Target Recruit Count: 80

Registration Number: NCT02426463

Locations: 🇫🇮
Department of Paediatrics and Adolescent Medicine, Turku University Hospital, Turku, Finland

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

Phase 3

Completed

Conditions: Withdrawal Symptoms

Interventions: Drug: Oxycodone/Naltrexone Capsules
Drug: Placebo
Drug: Oxycodone

First Posted Date: 2015-03-18

Last Posted Date: 2016-08-10

Lead Sponsor: Elite Laboratories, Inc

Target Recruit Count: 26

Registration Number: NCT02391571

Locations: 🇺🇸
Vince and Associates, Overland Park, Kansas, United States

Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery

Phase 4

Completed

Conditions: Disorder of Knee

Interventions: Drug: Oxycodone

First Posted Date: 2015-03-18

Last Posted Date: 2016-01-07

Lead Sponsor: International Clinical Research Institute

Target Recruit Count: 50

Registration Number: NCT02391844

Locations: 🇺🇸
International Clinical Research Institute, Overland Park, Kansas, United States

To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain

Phase 2

Completed

Conditions: Malignant Pain
Non-malignant Pain

Interventions: Drug: Oxycodone
Drug: Naloxone

First Posted Date: 2014-12-22

Last Posted Date: 2016-11-04

Lead Sponsor: Mundipharma Research GmbH & Co KG

Target Recruit Count: 155

Registration Number: NCT02321397

Early Use of Opioid in Radiation Mucositis

Phase 2

Completed

Conditions: Nutrition Disorders
Quality of Life

Interventions: Drug: Oxycodone

First Posted Date: 2014-12-05

Last Posted Date: 2018-07-17

Lead Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Target Recruit Count: 200

Registration Number: NCT02309437

Locations: 🇨🇳
People's Hospital of Boluo County, Huizhou, Guangdong, China
🇨🇳
Guangzhou Panyu Center Hospital, Guangzhou, Guangdong, China
🇨🇳
Cancer Center Of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 1 locations

Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery

Phase 4

Completed

Conditions: Nausea

Interventions: Drug: Hydromorphone
Drug: Oxycodone

First Posted Date: 2014-11-20

Last Posted Date: 2017-11-27

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 200

Registration Number: NCT02295124

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy